NWBO down 44.63% in 52 weeks is certainly not FLAT. NWBO employee presented the TLD at their special event at ASCO. No press release, website posting or SEC filing of the data is suspicious and likely reflects NWBO's management's worries that they would be at risk promoting the data -- SEC and DOJ have gone after biotechs that promote manipulated trial data publicly.
Market Data 
Markets 
AI
